Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zella 201: Alvocidib in MCL-1 Dependent AML
NCT02520011Phase 2Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2016
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of alvocidib in acute myeloid leukemia (AML), sponsored by Sumitomo Pharma America. Started Mar 2016; status: terminated.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02520011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520011.